ME-401, a NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-Kinase P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B-Cell LYMPHOID MALIGNANCIES

Hematological Oncology- United Kingdom

doi 10.1002/hon.2439_184

Full Text

Abstract

Available in

Date

Authors

Publisher

Wiley

Related search

Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers

Clinical Therapeutics
Pharmacology
2018English

Phosphoinositide 3-Kinase-Δ (PI3Kδ); Phosphoinositide 3-Kinase Catalytic Subunit Δ-Polypeptide (PI3KCD; P110δ)

Science-Business eXchange
2014Chinese

Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-Kinase Inhibitor Prodrug

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2012English

Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2013English

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

A Novel, Highly Potent and Selective Phosphodiesterase-9 Inhibitor for the Treatment of Sickle Cell Disease

Haematologica
Hematology
2019English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Novel Immunotherapies in Lymphoid Malignancies

Nature Reviews Clinical Oncology
Oncology
2015English

Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies

Blood Cancer Journal
OncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy